The research done by
BIOGENERA SpA has led to the identification and development of the first specific drug, the
anti-tumoral anti-MYCN BGA002, for the cure of
tumors of children with alterations of the tumoral gene MYCN (given a poor prognosis).
Within a few months BIOGENERA will start the phase 1 clinical studies, specifically in
Neuroblastoma (currently the more lethal tumor in children). On demonstrating its high level of innovation, the medicine has already obtained status of Orphan Drug for the cure of Neuroblastoma from the European Medicines Agency (EMA) and from the Food and Drug Administration (FDA) in USA, and of the group of
Soft Tissue Sarcomas (that include
Rhabdomyosarcoma and Synovial Sarcoma) by EMA.
Click here to get more information...
